That's what the Leo-bashing chorus wants. They've been screaming about what a "lousy" job he's done because he hasn't illegally tried to manipulate stock price, but instead has brought 4 drugs into clinical trials, with additional trials about to commence -- and at an incredibly low burn of company capital. No one with any common sense can possibly justify saying that Leo has done a bad job, when he saved this company from bankruptcy and has led it into success. Look at NNVC -- they've had many more years of operation than CTIX, and they STILL don't have a single clinical trial going.

Here's another article about the MDVN/Sanofi thing.

http://www.fiercebiotech.com/biotech/medivati...0ifQ%3D%3D

They talk about Sanofi's history of strong-arm tactics, and mention REGN. Who else has mentioned REGN as a role model? Oh yeah, it was Leo:

Quote:

---

Sanofi currently has a small group of cancer drugs on the market but is far behind its Big Pharma rivals in the latest classes of oncology R&D. In its Q1 results, its 6 marketed cancer drugs collectively made just $407 million, with none being market-leading.

It has been looking to rectify this in recent months, however, with a $1.8 billion cancer deal with Regeneron ($REGN) signed last summer and a host of deals with several oncology-focused biotechs also being penned at the start of the year.

---